|Published||Report Code||Available Format||Pages|
The global autoimmune disease diagnostics market generated $4,086.2 million revenue in 2019, and it is projected to witness a CAGR of 8.5% during 2020–2030. Rising discoveries of new biomarkers, increasing strategic development activities among key players, widespread burden of autoimmune diseases, and initiatives taken by several public and private organizations to raise awareness about autoimmune diseases are the key growth factors driving the autoimmune disease diagnostics industry.
The consumables and assay kits category in terms of product accounted for the larger share in the market. The category is further expected to retain its market dominance, owing to presence of large number of market players offering diagnostic test kits. Other factors responsible for the market growth in this category include rising prevalence of autoimmune diseases and growing research activities to identify the underlying cause of autoimmune diseases.
The autoimmune disease diagnostics market based on test type is classified into routine laboratory, inflammatory marker, autoantibodies and immunology, human leukocyte antigen (HLA), cytokine, flow cytometry, and others. Of these, the routine laboratory test category generated the largest revenue in 2019. It is also expected to remain largest and grow fastest in the forecast period. This can be ascribed to the fact the blood tests and serum tests are the initial procedures and require repeated diagnosis to check the abnormality in the bloodstream.
The RA category is projected to grow at the highest rate in the market, owing to the high prevalence of RA across the globe. The global prevalence and incidence of RA was also studied in the Global Burden of Diseases (GBD) 2017 report. Based on the statistical data, a total of 10,226,042 prevalent cases of RA were reported in 1990, which increased to 19,965,115 in 2017.
Hospitals were the largest end users of autoimmune disease diagnostics and related products in 2019. The category is further expected to remain largest in the market for autoimmune disease diagnostics during the forecast years. The increasing adoption of technologically advanced products, surging prevalence of chronic autoimmune diseases, rising number of awareness campaigns and conferences conducted by a number of public and private organizations, and improving healthcare infrastructure are some of the major factors contributing to the market growth.
During the historical period (2014–2019), North America accounted for the largest share in the market for autoimmune disease diagnostics, due to the rising healthcare spending, increasing prevalence of autoimmune diseases, surging geriatric population, and presence of big market players.
According to an article published by the National Institute of Environmental Health Sciences (NIEHS), NIH in May 2020, a total of 80 autoimmune diseases are known in the North American region, including type-1 diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), and RA, of which some are rare and difficult to diagnose. In 2019, approximately 24 million people in the U.S. were affected by autoimmune diseases. In addition, approximately eight million people in the U.S. have auto-antibodies blood molecules that can lead to the risk of developing autoimmune diseases. Therefore, all these factors are expected to boost the demand for the autoimmune disease diagnostics market.
One of the major factors responsible for driving the market growth in the Asia-Pacific (APAC) region is the presence of key players. Other major factors include cost-effective diagnostic tests, cheap labor, increasing geriatric population, and rise in initiatives by public and private organizations to raise awareness about autoimmune diseases. According to the World Bank data, the proportion of people aged 65 years and above in 2010 in Japan was 22.5%, which increased to 27.6% in 2018. Also, the number is projected to increase up to 60.0% by 2030. Furthermore, somehow similar scenario is observed for other APAC countries.
COVID-19 is having a positive impact on the global autoimmune disease diagnostics market. Due to this pandemic, the outlook for the industry has changed significantly, with predicted increase in the demand for diagnostic products in the short run, across the globe. Further, significant growth is likely to be witnessed with the proper lifting of lockdowns in several cities and resumption of import and export activities worldwide.
The prominent trend in the market for autoimmune disease diagnostics is the discovery of new biomarkers to diagnose autoimmune diseases. For instance, in August 2019, researchers of the University of Alberta identified a unique biological marker that can be used to identify the presence of rare autoimmune disease, myasthenia gravis. The biomarker can also be used to predict the course of the disease and identify new, personalized treatments, contributing to the significant growth of the autoimmune disease diagnostics industry.
Increasing awareness about autoimmune diseases is a major driver for the growth of the autoimmune disease diagnostics market. A number of conferences are expected to be held in later half of 2020 and throughout 2021 to raise awareness and serve as a platform to share knowledge about advancements in the field of autoimmune diseases. For instance, the 12th International Congress on Autoimmunity is to be held from November 28, 2020, to December 1, 2020, in Athens, Greece. Similarly, the International Conference on Autoimmune Diseases and Dermatology will be held on January 18–19, 2021, in Rome, Italy. The purpose of these conferences is to bring together academic scientists, researchers, and research scholars to exchange thoughts and share their experience and research results on all aspects of autoimmune diseases and dermatology. All these factors propel the growth of the market.
Increasing incidences and high prevalence of autoimmune diseases are boosting the growth of the market. According to the John Hopkin’s University, autoimmune diseases affect around 3% of the U.S. population every year, that is, approximately 10 million people. Also, the Myasthenia Gravis Foundation of America in June 2015 reported that myasthenia gravis was found in 14–20 individuals per each 100,000 U.S. population in 2014, affecting approximately 36,000–60,000 people in the country.
|Base Year (2019) Market Size||$4,086.2 million|
|Forecast Period (2020-2030) CAGR||8.5%|
|Report Coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies’ Strategical Developments, Product Benchmarking, Company Share Analysis, Company Profiling|
|Market Size by Segments||Product, Test Type, Application, End User, Region|
|Market Size of Geographies||U.S., Canada, Germany, France, Italy, U.K., Spain, Japan, China, India, Brazil, Mexico, Saudi Arabia, South Africa, Israel, U.A.E.|
|Secondary Sources and References (Partial List)||Centers for Disease Control and Prevention (CDC), Organisation for Economic Co-operation and Development (OECD), World Health Organization (WHO), American Heart Association (AHA), United States Food and Drug Administration (USFDA), National Institute of Environmental Health Sciences (NIEHS), American Autoimmune Related Diseases Association, National Institute for Health and Care Excellence (NICE) Note: Above listed references and organizations are partial; the detailed and complete list is available in the final report.|
The market for autoimmune disease diagnostics is consolidated in nature, with the presence of market players including Abbott Laboratories, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Siemens AG, Grifols S.A., Danaher Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and bioMérieux S.A.
In recent years, the players in the industry have engaged in strategic developments, such as product launches, in order to stay ahead of their competitors. For instance:
The autoimmune disease diagnostics market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
The autoimmune disease diagnostics market generated revenue of $4,086.2 million in 2019.
The autoimmune disease diagnostics industry will grow by 8.5% during 2020–2030.
The advent of novel biomarkers for diagnosis is the prominent trend in the autoimmune disease diagnostics market.
The surging public awareness of autoimmune diseases is the biggest growth driver of the autoimmune disease diagnostics industry.
Routine laboratory tests are the most widely performed in the autoimmune disease diagnostic market.